A near-infrared optogenetic system was developed for the controlled expression of therapeutics in engineered oncolytic bacteria, demonstrating significant anti-tumor efficacy in multiple tumor mouse models. This approach offers a non-invasive, customizable method for targeted solid tumor therapy and has broader applications in engineered living therapeutics.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu, B., Zhou, H., Tan, L., Siu, K. T. H. & Guan, X.-Y. Exploring treatment options in cancer: tumor treatment strategies. Sig. Transduct. Target. Ther. 9, 175 (2024). A review article that presents a comprehensive overview of emerging cancer therapies.
Zhou, S., Gravekamp, C., Bermudes, D. & Liu, K. Tumour-targeting bacteria engineered to fight cancer. Nat. Rev. Cancer 18, 727–743 (2018). A review article that presents the potential of engineered bacteria as a targeted delivery platform for cancer therapies.
Gurbatri, C. R., Arpaia, N. & Danino, T. Engineering bacteria as interactive cancer therapies. Science 378, 858–864 (2022). A review article that discusses the use of synthetic biology in optimizing bacterial therapies for cancer, focusing on enhancing therapeutic safety and effectiveness through engineered bacterial systems.
Gourinchas, G., Vide, U. & Winkler, A. Influence of the N-terminal segment and the PHY-tongue element on light-regulation in bacteriophytochromes. J. Biol. Chem. 294, 4498–4510 (2019). This paper reports the light-regulation mechanisms of chimeric photosensitive protein PadC4, which is an essential aspect of the NETMAP system.
Wilksch, J. J. et al. MrkH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 fimbriae expression. PLoS Pathog. 7, e1002204 (2011). This paper reports that MrkH is a c-di-GMP-dependent transcriptional activator in Klebsiella pneumoniae.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Qiao, L. et al. Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics. Nat. Cancer https://doi.org/10.1038/s43018-025-00932-3 (2025).
Rights and permissions
About this article
Cite this article
Near-infrared optogenetic engineering of bacteria for cancer therapy. Nat Cancer 6, 569–570 (2025). https://doi.org/10.1038/s43018-025-00931-4
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-025-00931-4
